Today's top medical abstracts
Rheumatology
Become a Member Today!
Email
Password
Remember me
Forgot your Password?

Invite Code?

Home
General Rheumatology
For Practicing
Rheumatologists
Conferences
Jobs
Newsletters
My Library
Topics in
Rheumatology
        Amyloidosis
        Autoimmune/Heritable
        Basic Science/Genetics
        Bone Metabolism
        Chr Fatigue/Fibromyalgia
        Clinical Pharmacology
        Connective Tissue Dz
        Diagnostics/Radiology
        Economics of Medicine
        Gout and Hyperuricemia
        Infectious Arthritis
        Osteoarthritis
        Other Arthritis
        Pediatric Rheumatology
        Popular Press
        Rheumatoid Arthritis
        Spondylarthropathies
        Systemic Lupus (SLE)
        Vasculitic Syndromes
 
Help
Resource Center
RSS News Feeds
Send Newsletter
to a Friend
 
Sponsor
For Practicing Rheumatologists
Today's Rheumatology News: VGX-1027 To Undergo Additional Testing For RA
D Scott Cunningham MD, PhD, MDLinx Rheumatology
Today's Rheumatology News: FDA Approves Actemra
D Scott Cunningham MD, PhD, MDLinx Rheumatology
From the Editors: New Clinical-Only Option for MDLinx!
Stephen Smith, MDLinx
  See all
spondyloarthritis;inhibition of osteoclasts Article Summary

Click the title below to leave the MDLinx Network and go to the Journal's Website
Inhibition of osteoclasts does not prevent joint ankylosis in a mouse model of spondyloarthritis
Rheumatology, 04/23/08
Print     Email This Article     Save in My Library   Free Abstract
Lories RJU et al. - Bone erosion at the enthesis does not necessarily precede entheseal ankylosis. Therefore the inflammation and new tissue formation in SpA are at least partially uncoupled events and may be different therapeutic targets.

Methods
  • Objective was to test whether inhibition of bone erosion by targeting osteoclasts, would prevent or influence joint ankylosis in a mouse model
  • Male DBA/1 mice from different litters were caged together at the age of 8 wks
  • Treatment with zoledronic acid (ZA) (100 ng/g) or placebo was started at the age of 10 wks/2wks
  • Clinical incidence and severity of arthritis were evaluated twice a week until the age of 26 wks
  • At this point, bone density measurements were performed, mice were sacrificed and severity of arthritis was evaluated by histology

Results
  • Treatment with ZA did not affect incidence or clinical severity of arthritis in male DBA/1 mice
  • ZA treatment increased bone mineral density and content as demonstrated by dual X-ray densitometry and peripheral quantitative CT
  • However, the treatment did not affect histomorphological appearance of arthritis or ankylosis

Read a Different Specialty
Allergy/Immunology
Anesthesiology
Cardiology
Dermatology
Drugs
Emergency Medicine
Endocrinology
ENT
Family Medicine
Gastroenterology
Hematology-Oncology
Infectious Disease
Internal Medicine
Nephrology
Neurology
OB/Gyn
Ophthalmology
Orthopedics
Pediatrics
Psychiatry
Pulmonology
Radiology
Rheumatology
Surgery
Urology
Profession Index
Dentist
Hospital Administrator
Nurse
    Medical Students
Nurse Practitioner
Pharma/Drug Marketer
    Pharmacist
Physician
Physician Assistants
Article Search
Keyword:
Search:
Published within:
Sort By:
Date Relevance
    
Sponsor
About MDLinx  |  Contact  |  Advertise with MDLinx  |  Site Map  |  Privacy Policy  |  Terms of Use  |  Sign Up For Newsletters  |  Recommend this Site

English |  Español |  Français |  Deutsch |  中文 |  Руccкий |  Norsk |  Nederlands |  Português |  Italiano

©1999-2008 MDLinx, Inc.